Vor Biopharma Ownership
| VOR Stock | USD 1.08 0.03 2.70% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Vor |
Vor Stock Ownership Analysis
About 32.0% of the company outstanding shares are owned by insiders. The company has Price to Book (P/B) ratio of 1.85. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Vor Biopharma recorded a loss per share of 1.64. The entity had not issued any dividends in recent years. Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell therapies for cancer patients. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Vor Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 135 people. For more information please call MBA MD at 617 655 6580 or visit https://www.vorbio.com.Vor Biopharma Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vor Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vor Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Vor Biopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Vor Biopharma Outstanding Bonds
Vor Biopharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Vor Biopharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Vor bonds can be classified according to their maturity, which is the date when Vor Biopharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| VOYA FINL INC Corp BondUS929089AB68 | View | |
| US929089AG55 Corp BondUS929089AG55 | View | |
| VOYA FINL INC Corp BondUS929089AF72 | View | |
| VOYA FINL INC Corp BondUS929089AC42 | View | |
| VNO 215 01 JUN 26 Corp BondUS929043AK39 | View | |
| VNO 34 01 JUN 31 Corp BondUS929043AL12 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Additional Tools for Vor Stock Analysis
When running Vor Biopharma's price analysis, check to measure Vor Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vor Biopharma is operating at the current time. Most of Vor Biopharma's value examination focuses on studying past and present price action to predict the probability of Vor Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vor Biopharma's price. Additionally, you may evaluate how the addition of Vor Biopharma to your portfolios can decrease your overall portfolio volatility.